Abstract
Several epidemiologic studies have shown that obesity represents an independent risk factor for the development of cardiovascular diseases, including hypertension, myocardial ischemic disease, and cardiac arrhythmias. One of the most appealing concepts in obesity-related hypertension is that a specific etiology can be identified. There is now substantial evidence that human obesity is characterized by abnormalities in sympathetic cardiovascular control. The application of sensitive techniques to assess sympathetic nervous system (SNS) activity in humans, including catecholamine levels, norepinephrine (NE) spillover techniques, and microneurography have furthered this concept. Catecholamine levels in obesity have been conflicting, with high, normal, and low levels reported. However, studies examining weight loss have found that the fall in blood pressure (BP) was highly correlated with reductions in plasma NE. Examination of NE spillover in obesity has shown regional overactivity in the kidneys. High renal SNS activity could lead to sodium retention and abnormal glomerular hemodynamics that could raise BP. Microneurography, which determines muscle sympathetic outflow, has shown consistent elevation in obesity, but no difference between normotensive and hypertensive obesity. However, the hyperinsulinemia of obesity may act in concert with the SNS to elevate BP, as the combination of the two seems to produce vascular constriction. Leptin also has several cardiovascular actions that may contribute to BP regulation. Epidemiologic studies also found that SNS activity predicts hypertension in obese subjects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2439.
Mancia G, DiRienzo M, Parati G, Grassi G: Sympathetic activity, BP variability and end organ damage in hypertension. J Hum Hypertens 1997, (Suppl 1):S3–S8. One of first studies to equate level of sympathetic activity to target organ damage.
Landsberg L: Insulin and the sympathetic nervous system in the pathophysiology of hypertension. Blood Press Suppl 1996, 1:25–29.
Schwartz JH, Young JB, Landsberg L: Effect of dietary fat on sympathetic nervous system activity in the rat. J Clin Invest 1983, 72:361–370.
Ward KD, Sparrow D, Landsberg L, et al.: Influence of insulin, sympathetic nervous system activity and obesity on BP: the Normative Aging Study. J Hypertens 1996, 14(3):301–308. First epidemiologic study on a relationship between body fat, sympathetic nervous system, and blood pressure.
Masuo K, Mikami H, Ogihara T, Tuck ML: Sympathetic nerve hyperactivity precedes hyperinsulinemia and BP elevation in a young, nonobese Japanese population. Am J Hypertens 1997, 10:77–83. Sympathetic nervous system activity may rise early in the onset of hypertension.
Masuo K, Mikami H, Ogihara T, Tuck ML: Differences in insulin and sympathetic responses to glucose ingestion due to family history of hypertension. Am J Hypertens 1996, 9:739–745.
Hjemdahl P, Fiberg P: Biochemical assessment of sympathetic activity and prejunctional modulation of noradrenaline release in humans. J Hypertens 1996, 14:147–150.
Grossman E, Chang PC, Hoffman A, et al.: Tracer norepinephrine kinetics: dependence on regional blood flow and the site of infusion. Am J Physiol 1991, 260:R946-R952.
Eisenhofer G, Esler MD, Goldstein DS. Kopin U: Neuronal uptake, metabolism, and release of tritium-labeled norepinephrine during assessment of its plasma kinetics. Am J Physiol 1991, 261:E505-E515.
Wallin BG, Delius W, Hagbarth K-E: Comparison of sympathoadrenomedullary function. Circ Res 1973, 33:9–21.
Anderson EA, Sinkey CA, Lawton WJ, Mark AL: Elevated sympathetic nerve activity in borderline hypertensive man: Evidence from direct intraneuronal recordings. Hypertension 1998, 14:177–183.
Akselrod S, Gordon D, Madwed JB, et al.: Hemodynamic regulation: Investigation by spectral analysis. Am J Physiol 1985, 249:H867-H875.
Young JB, Macdonald IA: Sympathoadrenal activity in human obesity: hetergeneity of findings since 1980. Int J Obes Relat Metab Disord 1992, 16:959–967.
Tuck ML: Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992, 19[Suppl I]:I67-I77.
Tuck ML, Sowers JR, Dornfeld L, et al.: Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) 1983, 102:252–257.
Sowers JR, Whitfield L, Catania RA, et al.: Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 1982, 54:1181–1186.
Kushiro T, Kobayashi F, Osada H, et al.: Role or sympathetic activity in blood pressure reduction with a low calorie regimen. Hypertension 1991, 17:965–968.
Maxwell MH, Heber D, Waks AU, Tuck ML: Role of insulin and norepinephrine in the hypertension of obesity. Am J Hypertens 1994, 7:402–408.
Goldstein DS: Plasma catecholamines in essential hypertension: An analytic review. Hypertension 1983, 5:86–96.
Csabi G, Molnar D, Hartmann G: Urinary sodium excretion: association with hyperinsulinaemia, hypertension and sympathetic nervous system activation in obese and control children. Eur J Pediatr 1996, 155(10):895–897.
Esler MD, Lambert G, Jennings GL: Increased regional sympathetic nerve activity in human hypertension: causes and consequences. J Hypertens 1990, 8(Suppl 7):S53-S57.
Vaz M, Jennings G, Turner A, et al.: Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1977, 6:3423–3429.
West D, Wehberg KE, Kieswetter K, Granger J: Blunted natriuretic response to an acute sodium load in obese hypertensive dogs. Hypertension 1992, 19(Suppl I):I196-I110.
Esler M, Lambert G, Vas M, et al.: Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Clin Exp Hypertens 1997, 19:577–590.
Anderson B, Elam M, Wallin BG, et al.: Effect of energy restricted diet on sympathetic muscle nerve activity in obese women. Hypertension 1991, 18:783–789.
Jones PP, Snitker S, Skinner JS, Ravussin E: Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. Am J Physiol 1996, 270:363–366.
Spraul M, Ravussin E, Fontvielle AM, et al.: Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. J Clin Invest 1993, 92:1730–1735.
Scherrer U, Randin D, Tappy L, et al.: Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994, 89:2634–2640.
Grassi G, Seravalle G, Cattaneo BM, et al.: Sympathetic activation in obese normotensive subjects. Hypertension 1995, 25[Part I]:560–563.
Grassi G, Seravalle G, Colombo M, et al.: Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998, 97:2037–2042.
Gudbjornsdottir S, Lonnroth P, Sverrisdottir YB, et al.: Sympathetic nerve activity and insulin in obese normotensive and hypertensive men. Hypertension 1996, 27:276–280.
Narkiewicz K, van de Borne PJ, Cooley RL, et al.: Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998, 98:772–776. Maybe all increased SNS activity in obesity is due to obstructive sleep apnea.
Grassi G, Colombo M, Seravalle G, et al.: Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998, 31:64–67.
Rowe JW, Young JB, Minaker KL, et al.: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981, 30:219–225.
O’ Hare JA, Minaker KL, et al.: Effect of insulin on plasma norepinephrine and 3,4 dihydroxyphenylalanine in obese men. Metabolism 1989, 38:322–329.
Berne C, Fagius J, Pollare, Hjemdahl P: The sympathetic response to euglycemic hyperinsulinemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetalogia 1992, 35:873–879.
Lembo C, Napoli R, Capaldo B, et al.: Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest 1992, 90:24–29.
Lembo G, Vecchione C, Iaccarino G, Trimarco B: The crosstalk between insulin and the sympathetic nervous system: possible implications in the pathogenesis of essential hypertension. Blood Press Suppl 1996, 1:38–42.
Anderson EA, Mark AL: The vasodilatory action of insulin. Implications for the insulin hypothesis in hypertension. Hypertension 1993, 21:136–141.
Corry DB, Tuck ML: Insulin and glucoregulatory hormones: implications for antihypertensive therapy. In Calcium Antagonists in Clinical Medicine. Edited by Epstein, M. Philadelphia: Hanley and Belfus; 1998:217–241.
Barron AD: Insulin and the vasculature-old actors, new roles. J Invest Med 1996, 8:406–412.
Scherrer U, Randin D, Vollenweinder P, Nicod P: Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest 1994, 94:2511–2515.
Hall JE, Brands MW, Kivlighn SD, et al.: Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines. Hypertension 1990, 15:519–527.
Gudbjornsdottir S, Elam M, Sellgren J, Anderson E: Insulin increases forearm resistance in obese, insulin resistant hypertensives, J Hypertens 1966, 14:91–97.
Carrol JF, Jones AE, Hester RL, et al.: Reduced cardiac contractile responsiveness to isoproteronol in obese rabbits. Hypertension 1997, 30:1367–1381.
Piccirillo G, Vetta F, Fimognari FL, et al.: Power spectral analysis of heart rate variability in obese subjects: evidence of decreased cardiac sympathetic responsiveness. Int J Obese Relat Metab Disord 1997, 20:825–829.
Haynes WG, Morgan DA, Walsh SA, et al.: Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270–278.
Haynes WG, Sivitz WI, Morgan DA, et al.: Sympathetic and cardiorenal actions of leptin. Hypertension 1997, 30:619–623.
Schmieder RE, Gatzka C, Schachinger H, et al.: Obesity as a determinant for response to antihypertensive treatment. BMJ 1993, 307:537–540.
Reisin E, Weed SG: The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine. J Hypertens 1992, 10:489–493.
Reisin E, Weir M, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension 1997, 30:140–145.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corry, D.B., Tuck, M.L. Obesity, hypertension, and sympathetic nervous system activity. Current Science Inc 1, 119–126 (1999). https://doi.org/10.1007/s11906-999-0005-x
Issue Date:
DOI: https://doi.org/10.1007/s11906-999-0005-x